The effects of activated eosinophils and neutrophils on guinea pig airway epithelium in vitro.

Epithelial shedding is a characteristic feature of asthmatic airways and has been attributed to eosinophil products. We have examined the interaction of purified intraperitoneal guinea pig eosinophils with or without platelet-activating factor (PAF, 10(-7) M) or lyso-PAF (10(-7) M) with guinea pig tracheal epithelium in vitro. At 0, 4, 14, and 24 h, the percentage of ciliation of the tracheal circumference (CTC) was measured by light microscopy and the ciliary beat frequency (CBF) by photometry. PAF-activated eosinophils (50 x 10(6) cells/ml) disrupted the epithelium, mean CBF and CTC being reduced by 77.8 +/- 5.8% (mean +/- SEM; P less than 0.001 versus control) and 94.2 +/- 1.4% (P less than 0.001) over 24 h, respectively. PAF (10(-7) M) alone had no significant effect. Lyso-PAF with eosinophils (50 x 10(6) cells/ml) also reduced mean CBF and CTC but to a lesser extent. Eosinophils alone also led to a reduction of 36.2 +/- 11.4% in mean CBF and 53.0 +/- 15.5% in CTC, but these changes were not significant. The PAF antagonist, WEB 2086 (10(-6) M), significantly inhibited the mean CBF and CTC reduction due to PAF-activated eosinophils by 61.5 +/- 17.2% (P less than 0.01) and 20.8 +/- 6.5% (P less than 0.05), respectively. In addition, catalase (1,125 U/ml) partially inhibited the mean CBF and CTC reduction induced by PAF-activated eosinophils. Intraperitoneal neutrophils (PMN) (50 x 10(6) cells/ml) also disrupted epithelium but to a lesser extent (24-h reduction: 34.2 +/- 12.7% for mean CBF and 60.2 +/- 13.2% for CTC, respectively). Stimulation with PAF (10(-7) M) had no further effect. Marked exfoliation of the epithelial layer was observed after 14 h of incubation with activated eosinophils. We concluded the PAF-activated eosinophils are capable of grossly disrupting ciliated epithelium and may contribute to epithelial damage observed in asthma.

[1]  G. Zimmerman,et al.  Platelet-activating Factor , 1991 .

[2]  K. Chung,et al.  Stimulation of degranulation from human eosinophils by platelet-activating factor. , 1989, Journal of immunology.

[3]  P. Barnes,et al.  PAF-receptors on eosinophils: identification with a novel ligand, [3H]WEB 2086. , 1989, Biochemical pharmacology.

[4]  D. Loegering,et al.  Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. , 1989, The American review of respiratory disease.

[5]  K. Chung,et al.  Characterization of platelet‐activating factor‐induced elevation of cytosolic free calcium concentration in eosinophils , 1989, FEBS letters.

[6]  R. Wilson.  Secondary ciliary dysfunction. , 1988, Clinical science.

[7]  N. Flavahan,et al.  The eosinophil as a mediator of damage to respiratory epithelium: a model for bronchial hyperreactivity. , 1988, The Journal of allergy and clinical immunology.

[8]  K. Chung,et al.  Platelet-activating factor as a mediator of allergic disease. , 1988, The Journal of allergy and clinical immunology.

[9]  P. Henson,et al.  Stimulation of eosinophil adherence to human vascular endothelial cells in vitro by platelet-activating factor. , 1988, Journal of immunology.

[10]  K. Chung,et al.  Inflammatory mediators and asthma. , 1988, Pharmacological reviews.

[11]  N. Thomson,et al.  Asthma : basic mechanisms and clinical management , 1988 .

[12]  N. Flavahan,et al.  Human eosinophil major basic protein causes hyperreactivity of respiratory smooth muscle. Role of the epithelium. , 1988, The American review of respiratory disease.

[13]  A. Wardlaw,et al.  Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity. , 1988, The American review of respiratory disease.

[14]  D. Loegering,et al.  The effect of purified human eosinophil major basic protein on mammalian ciliary activity. , 2015, The American review of respiratory disease.

[15]  L. Touqui,et al.  Perspectives in platelet-activating factor research. , 1987, Pharmacological reviews.

[16]  K. Weber,et al.  Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. , 1987, The Journal of pharmacology and experimental therapeutics.

[17]  D. Loegering,et al.  The injurious effect of eosinophil peroxidase, hydrogen peroxide, and halides on pneumocytes in vitro. , 1987, The Journal of allergy and clinical immunology.

[18]  A. Wardlaw,et al.  Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. , 1986, The Journal of clinical investigation.

[19]  L. Koenderman,et al.  Platelet-activating factor (PAF-acether) induced leukotriene C4 formation and luminol dependent chemiluminescence by human eosinophils. , 1986, Pharmacological research communications.

[20]  P. Venge,et al.  Mechanism of membrane damage mediated by human eosinophil cationic protein , 1986, Nature.

[21]  G. Gleich,et al.  The eosinophil and the pathophysiology of asthma. , 1986, The Journal of allergy and clinical immunology.

[22]  W. Burman,et al.  Oxidant-mediated ciliary dysfunction. Possible role in airway disease. , 1986, Chest.

[23]  A. Wardlaw,et al.  Platelet activating factor enhances eosinophil cytotoxicity in vitro , 1986 .

[24]  G. Gleich,et al.  The eosinophilic leukocyte: structure and function. , 1986, Advances in immunology.

[25]  W. Busse,et al.  Comparison of superoxide generation and luminol-dependent chemiluminescence with eosinophils and neutrophils from normal individuals. , 1985, The Journal of laboratory and clinical medicine.

[26]  M. Peters,et al.  Increased numbers of hypodense eosinophils in the blood of patients with bronchial asthma. , 1985, The American review of respiratory disease.

[27]  D. Loegering,et al.  Eosinophil- and eosinophil granule-mediated pneumocyte injury. , 1985, The Journal of allergy and clinical immunology.

[28]  A. Someya,et al.  Response of superoxide anion production by guinea pig eosinophils to various soluble stimuli: comparison to neutrophils. , 1985, Archives of biochemistry and biophysics.

[29]  M. Yazdanbakhsh,et al.  Characterization of the interaction of human eosinophils and neutrophils with opsonized particles. , 1985, Journal of immunology.

[30]  M. Peters,et al.  Calcium ionophore A23187 calcium-dependent cytolytic degranulation in human eosinophils. , 1985, Journal of immunology.

[31]  D. Loegering,et al.  Comparative toxicity of purified human eosinophil granule cationic proteins for schistosomula of Schistosoma mansoni. , 1985, The American journal of tropical medicine and hygiene.

[32]  T. Haahtela,et al.  Damage of the airway epithelium and bronchial reactivity in patients with asthma. , 1985, The American review of respiratory disease.

[33]  P. Venge,et al.  Human eosinophil peroxidase: purification and characterization. , 1985, Journal of immunology.

[34]  H. Sluiter,et al.  Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. , 1985, The American review of respiratory disease.

[35]  R. Crystal,et al.  Eosinophil-mediated injury to lung parenchymal cells and interstitial matrix. A possible role for eosinophils in chronic inflammatory disorders of the lower respiratory tract. , 1984, The Journal of clinical investigation.

[36]  I. Olsson,et al.  Monoclonal antibodies distinguish between storage and secreted forms of eosinophil cationic protein , 1984, Nature.

[37]  R. Smith,et al.  Stimulation of the human neutrophil superoxide anion-generating system with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3- phosphorylcholine. , 1984, Biochemical pharmacology.

[38]  B. Babior.  The respiratory burst of phagocytes. , 1984, The Journal of clinical investigation.

[39]  J. Harley,et al.  Distinctive cationic proteins of the human eosinophil granule: major basic protein, eosinophil cationic protein, and eosinophil-derived neurotoxin. , 1983, Journal of immunology.

[40]  T. Coates,et al.  Metabolic, membrane, and functional responses of human polymorphonuclear leukocytes to platelet-activating factor , 1982 .

[41]  J. O'flaherty,et al.  Platelet activating factor. Stimulation of the lipoxygenase pathway in polymorphonuclear leukocytes by 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine. , 1982, The Journal of biological chemistry.

[42]  L. McManus,et al.  Activation of human neutrophils with 1-O-hexadecyl/octadecyl-2-acetyl-sn-glycerol-3-phosphorylcholine (platelet activating factor). , 1981, Journal of immunology.

[43]  D. Durack,et al.  Purification of human eosinophil-derived neurotoxin. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Vadas,et al.  Antibody-dependent eosinophil-mediated damage to schistosomula of Schistosoma mansoni: lack of requirement for oxidative metabolism. , 1981, Journal of immunology.

[45]  J. O'flaherty,et al.  1-O-Alkyl-sn-glyceryl-3-phosphorylcholines: a novel class of neutrophil stimulants. , 1981, The American journal of pathology.

[46]  J. Rutland,et al.  NON-INVASIVE SAMPLING OF NASAL CILIA FOR MEASUREMENT OF BEAT FREQUENCY AND STUDY OF ULTRASTRUCTURE , 1980, The Lancet.

[47]  I. Gärtner.  Separation of human eosinophils in density gradients of polyvinylpyrrolidone-coated silica gel (Percoll). , 1980, Immunology.

[48]  D. Loegering,et al.  Cytotoxic effects of the guinea pig eosinophil major basic protein on tracheal epithelium. , 1980, Laboratory investigation; a journal of technical methods and pathology.

[49]  R. Sturrock,et al.  The mechansim of antibody-dependent, eosinophil-mediated damage to schistosomula of Schistosoma mansoni in vitro: a study by phase-contrast and electron microscopy. , 1978, Journal of cell science.

[50]  S. Pincus.  Production of eosinophil-rich guinea pig peritoneal exudates. , 1978, Blood.

[51]  Y. Tanizaki,et al.  Basophils in bronchial asthma with reference to reagin‐type allergy , 1973, Clinical allergy.

[52]  S. Wolff,et al.  Bactericidal and metabolic properties of human eosinophils. , 1972, Blood.

[53]  M. Dunnill.  THE PATHOLOGY OF ASTHMA, WITH SPECIAL REFERENCE TO CHANGES IN THE BRONCHIAL MUCOSA , 1960, Journal of clinical pathology.